Takeda Pharmaceutical revenue and financials
¥5,766.00Change from previous close: +0.82%Absolute change: +¥47.00
In the fiscal year ended March 2026, Takeda Pharmaceutical reported revenue of ¥4.51T (−1.66% year over year). The net loss was ¥152.39B.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −1.66%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3.4%
- FY to Mar 2025: 2.4%
Financial data
Amounts in millions of JPY; per-share values in JPY; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 | FY to Mar 2020 | FY to Mar 2019 | FY to Mar 2018 | FY to Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1,041,431 | 1,057,182 | 716,344 | 977,156 | 1,123,105 | 1,010,931 | 669,752 | 328,479 | 377,854 | 261,363 |
| Depreciation and amortization | 721,127 | 761,396 | 728,002 | 664,400 | 583,151 | 559,671 | 583,649 | 247,691 | 182,127 | 171,426 |
| Capital expenditure | -414,659 | -200,795 | -175,420 | -140,657 | -123,252 | -111,206 | -127,082 | -77,677 | -67,005 | -61,660 |
| Investing cash flow | -369,141 | -367,060 | -463,862 | -607,102 | — | — | — | — | — | — |
| Financing cash flow | -496,820 | -751,425 | -354,416 | -709,148 | — | — | — | — | — | — |
| Dividends paid | -311,901 | -302,498 | -287,188 | -279,416 | -283,665 | -283,357 | -282,582 | -142,952 | -141,893 | -141,688 |
| Share repurchases | -51,603 | -51,860 | -2,326 | -26,929 | -77,531 | -2,141 | -3,737 | -1,172 | -18,756 | -23,117 |
| Debt issued | 586,060 | 1,051,950 | 377,000 | 115,000 | — | — | — | — | — | — |
| Debt repaid | -584,984 | -1,366,264 | -375,487 | -400,071 | — | — | — | — | — | — |
| Effect of exchange rates | 34,472 | -11,385 | 26,204 | 22,929 | — | — | — | — | — | — |
| Net change in cash | 175,469 | -61,302 | -101,934 | -339,094 | — | — | — | — | — | — |
| Free cash flow | 626,772 | 677,557 | 235,614 | 343,467 | — | — | — | — | — | — |